Ipsen nominates Pascal Touchon to its Board of Directors as new independent director
04 Setembro 2023 - 2:00AM
Ipsen nominates Pascal Touchon to its Board of Directors as new
independent director
PARIS, FRANCE, 4 September 2023
– Ipsen (Euronext: IPN; ADR: IPSEY) announced today the co-optation
of Pascal Touchon to its Board as an independent director,
effective 4 October 2023, following the decision of Paul Sekhri to
step down from his director role on this date due to other
professional commitments.
Pascal Touchon is an experienced biotech CEO and
pharma leader and is the CEO of ATARA Biotherapeutics. He has
previously held leadership positions at Novartis and Servier and
has served on the Board of Directors of several biotechs. He brings
with him a successful track record in US biotech and global pharma,
with 30-plus years of experience. He is a graduate of INSEAD, where
he received his MBA.
Following this co-optation, the Board of
Directors will remain composed of fourteen directors: seven women1
and seven men, including four independent directors and two
directors representing the employees.
Pascal Touchon will be a member of the
Nomination Committee, the Innovation and Development Committee and
the Audit Committee.
At the next Shareholder’s meeting there will be
a request for ratification of this decision, which would remain in
effect for the remainder of Paul Sekhri’s term of office, until the
2026 Shareholder’s meeting.
On behalf of the Board of Directors, Chairman of
the Board Marc de Garidel thanks Paul Sekhri for his strong
contribution and involvement to Ipsen’s Board and Committees over
the last five years.
ENDS
About Ipsen Ipsen is a
global, mid-sized biopharmaceutical company focused on
transformative medicines in Oncology, Rare Disease and
Neuroscience. With total sales of €3.0bn in FY 2022, Ipsen sells
medicines in over 100 countries. Alongside its
external-innovation strategy, the Company’s research and
development efforts are focused on its innovative and
differentiated technological platforms located in the heart of
leading biotechnological and life-science hubs: Paris-Saclay,
France; Oxford, U.K.; Cambridge, U.S.; Shanghai, China. Ipsen has
around 5,300 colleagues worldwide and is listed in Paris (Euronext:
IPN) and in the U.S. through a Sponsored Level I American
Depositary Receipt program (ADR: IPSEY). For more information,
visit ipsen.com
For further information:
Contacts Investors
|
|
Craig MarksVice President, Investor Relations+44
(0)7584 349 193 |
Nicolas BoglerSenior Manager, Investor
Relations+33 6 52 19 98 92 |
Media |
|
Amy
WolfVP, Head of Corporate Brand Strategy &
Communications+41 79 576 07 23 |
Ioana
PiscociuSenior ManagerGlobal Media Relations +33 6 69 09
12 96 |
Ipsen’s forward-looking
statementsThe forward-looking statements, objectives and
targets contained herein are based on Ipsen’s management strategy,
current views and assumptions. Such statements involve known and
unknown risks and uncertainties that may cause actual results,
performance or events to differ materially from those anticipated
herein. All of the above risks could affect Ipsen’s future ability
to achieve its financial targets, which were set assuming
reasonable macroeconomic conditions based on the information
available today. Use of the words ‘believes’, ‘anticipates’ and
‘expects’ and similar expressions are intended to identify
forward-looking statements, including Ipsen’s expectations
regarding future events, including regulatory filings and
determinations. Moreover, the targets described in this document
were prepared without taking into account external-growth
assumptions and potential future acquisitions, which may alter
these parameters. These objectives are based on data and
assumptions regarded as reasonable by Ipsen. These targets depend
on conditions or facts likely to happen in the future, and not
exclusively on historical data. Actual results may depart
significantly from these targets given the occurrence of certain
risks and uncertainties, notably the fact that a promising medicine
in early development phase or clinical trial may end up never being
launched on the market or reaching its commercial targets, notably
for regulatory or competition reasons. Ipsen must face or might
face competition from generic medicine that might translate into a
loss of market share. Furthermore, the research and development
process involves several stages each of which involves the
substantial risk that Ipsen may fail to achieve its objectives and
be forced to abandon its efforts with regards to a medicine in
which it has invested significant sums. Therefore, Ipsen cannot be
certain that favorable results obtained during preclinical trials
will be confirmed subsequently during clinical trials, or that the
results of clinical trials will be sufficient to demonstrate the
safe and effective nature of the medicine concerned. There can be
no guarantees a medicine will receive the necessary regulatory
approvals or that the medicine will prove to be commercially
successful. If underlying assumptions prove inaccurate or risks or
uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements. Other risks
and uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including
interest rate and currency exchange rate fluctuations; the impact
of pharmaceutical industry regulation and healthcare legislation;
global trends toward healthcare cost containment; technological
advances, new medicine and patents attained by competitors;
challenges inherent in new-medicine development, including
obtaining regulatory approval; Ipsen's ability to accurately
predict future market conditions; manufacturing difficulties or
delays; financial instability of international economies and
sovereign risk; dependence on the effectiveness of Ipsen’s patents
and other protections for innovative medicines; and the exposure to
litigation, including patent litigation, and/or regulatory actions.
Ipsen also depends on third parties to develop and market some of
its medicines which could potentially generate substantial
royalties; these partners could behave in such ways which could
cause damage to Ipsen’s activities and financial results. Ipsen
cannot be certain that its partners will fulfil their obligations.
It might be unable to obtain any benefit from those agreements. A
default by any of Ipsen’s partners could generate lower revenues
than expected. Such situations could have a negative impact on
Ipsen’s business, financial position or performance. Ipsen
expressly disclaims any obligation or undertaking to update or
revise any forward-looking statements, targets or estimates
contained in this press release to reflect any change in events,
conditions, assumptions or circumstances on which any such
statements are based, unless so required by applicable law. Ipsen’s
business is subject to the risk factors outlined in its
registration documents filed with the French Autorité des
Marchés Financiers. The risks and uncertainties set out are not
exhaustive and the reader is advised to refer to Ipsen’s latest
Universal Registration Document, available on ipsen.com.
1 Representing 42%, the Directors representing the employees not
being taken into account in this calculation, pursuant to article
L. 225-18-1 of the French Code of Commerce
- Ipsen PR_Pascal Touchon Appointment_04092023
Ipsen (EU:IPN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Ipsen (EU:IPN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024